Impact of 24-week dapagliflozin treatment on body weight, body composition, and cardiac risk indicators of patients with type-2 diabetes mellitus.

Pinar Akhanli Sema Hepşen İsmail Emre Arslan Hakan Düğer Hayri Bostan Muhammed Kizilgul Bekir Ucan Mustafa Ozbek

Published in: Turkish journal of medical sciences (2023)

It was observed that dapagliflozin not only contributes to weight and fat loss but also has positive impacts on cardiovascular and atherosclerotic indicators.

Keyphrases

body composition
body weight
end stage renal disease
resistance training
ejection fraction
chronic kidney disease
adipose tissue
prognostic factors
left ventricular
randomized controlled trial
clinical trial
heart failure
patient reported outcomes
weight gain